WPP Gains, GSK Falls, Monte Paschi Up

Nuvalent Merger; Apple Skepticism; Applied Digital Deal

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - Nuvalent (NUVL) shares are higher on news GSK agreed to buy Nuvalent for $10.6 billion, securing a US biotech firm developing treatments for lung cancer. - Apple (AAPL) shares are lower after the company detailed the latest generation of its AI platform, which is focused on its Siri digital assistant. The event received mixed reviews. - Applied Digital (APLD) is rising on news of a 15-year hyperscaler lease deal at Delta Forge 2. - Vail Reports (MTN) is dropping after the ski resort operator cut its net income guidance for the full year, attributing the reduction to “historically challenging” weather conditions in the western US. The guidance missed the average analyst estimate. - Mission Produce (AVO) shares sank after the avocado supplier reported adjusted earnings per share for the second quarter that missed the average analyst estimate. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

GSK Deal, Fevertree Up, Seraphim Soars

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - GSK agreed to buy Nuvalent Inc. in a deal valued at $10.6 billion (7.9 billion pounds), adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. - Fever-Tree shares rise as much 8.2% to the highest in a month after the company said it was on track to meet expectations and extended its buyback program. - Seraphim Space Investment Trust shares rise as much as 26%, their biggest jump in almost three years, after the fund said the fair value of Iceye, its largest holding, had doubled after a funding round. Shares of Molten Ventures, which also invests in Iceye, gain as much as 12%. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

WPP Gains, GSK Falls, Monte Paschi Up

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - WPP gains 4.7% on new buy rating from Berenberg. Berenberg initiated coverage of WPP with a recommendation of buy. Their price target was set to 405 pence, implying a 54% increase from last price - GSK agreed to buy Nuvalent Inc. in a deal valued at $10.6 billion (7.9 billion pounds), adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. - Italy’s Finance Minister Giancarlo Giorgetti indicated the government won’t interfere in any battle for control of Monte Paschi saying price will determine whether Banco BPM or Intesa Sanpaolo prevail. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

Intel Rises, Mission Produce Drops, Tango Therapeutics Surges

Today's biggest winners and losers in the stock market, a look at the notable movers: On this episode of Stock Movers: - Intel (INTC) shares rose after the Information reported that Alphabet Inc.'s Google will rely on it for more than 3 million specialized AI chips in 2028. Google decided to tap Intel to make some of its tensor processing units — TPUs for short — after months of testing the chipmaker’s technology, the Information said Monday, citing two unnamed sources. - Mission Produce (AVO) swung to a loss and reported lower revenue in the fiscal second quarter due to low avocado prices and harvest delays. The company reported a loss and lower revenue, but volumes grew and supply conditions have improved with better pricing and margins since the second quarter. - Tango Therapeutics (TNGX) jumped as much as 48% after initial results of a study showed a combination of its drug and a Revolution Medicines Inc. medicine shrunk tumors in advanced pancreatic cancer patients. Tumor size decreased significantly in 11 of 12 pancreatic cancer patients who received the two-drug combination, Tango said in a statement Monday. The data includes two people whose responses had not yet been confirmed by a second scan. The biotech company said that it plans to begin a final stage trial combining its drug, vopimetostat, with Revolution’s daraxonrasib for the initial treatment of advanced pancreatic cancer. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

Closing Bell: Sportradar Jumps, Campbell's Down, Ensign Drop

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Katie Griefeld, Carol Massar and Tim Stenovec. - Sportradar (SRAD) shares jump as much as 11% on Monday, the most intraday since April 2025, after the sports technology company announced a multi-year global agreement with Kalshi to provide sports data for the prediction market platform. - Campbell’s (CPB) shares are down 1.1%, reversing a premarket gain, after the canned soup maker said during its conference call that it expects an additional 2% to 3% of inflation for next year should oil remain around $100 a barrel. BNP Paribas says there’s little in today’s commentary that could excite investors. - Shares of Ensign Group (ENSG), which operates nursing homes and rehab clinics, fall as much as 7.4%, the most since February 2025, following a report from Hunterbrook Media. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.